A Model of Care for Familial Hypercholesterolaemia: Key Role for Clinical Biochemistry

Gerald Watts, David Sullivan, Frank van Bockxmeer, Nicola Poplawski, Ian Hamilton-Craig, Peter Clifton, Richard O'Brien, Peter George, John Burnett

    Research output: Contribution to journalComment/debate

    12 Citations (Scopus)

    Abstract

    Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.

    Original languageEnglish
    Pages (from-to)25-31
    Number of pages7
    JournalClinical Biochemist Reviews
    Volume33
    Issue number1
    Publication statusPublished - 2012

    Fingerprint Dive into the research topics of 'A Model of Care for Familial Hypercholesterolaemia: Key Role for Clinical Biochemistry'. Together they form a unique fingerprint.

  • Cite this

    Watts, G., Sullivan, D., van Bockxmeer, F., Poplawski, N., Hamilton-Craig, I., Clifton, P., O'Brien, R., George, P., & Burnett, J. (2012). A Model of Care for Familial Hypercholesterolaemia: Key Role for Clinical Biochemistry. Clinical Biochemist Reviews, 33(1), 25-31.